Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition?

Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition? Opinion EDITORIAL Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition? Hadine Joffe, MD, MSc; Martha Hickey, BA(Hons), MBChB, MSc, FRCOG, FRANZCOG, MD In this issue of JAMA Psychiatry, Gordon et al report results of this subgroup (42 women), this observation is consistent with larger prospective studies indicating that the early peri- from a 12-month randomized clinical trial of estrogen plus pro- gestin hormone therapy (HT) vs placebo for the prevention of menopause confers heightened vulnerability to depressive 8,9 depressive symptoms in 172 symptoms, perhaps owing to greater variability in circulat- euthymic perimenopausal ing estradiol concentrations during this reproductive stage. Related article page 149 and early postmenopausal A limitation of this study is that we do not know whether women. Using a random- women who developed elevated Center for Epidemiological ized, parallel-arm placebo-controlled design, they found that Studies Depression Scale scores were experiencing an epi- women assigned to placebo were twice as likely to develop sode of major depression because the sensitivity and speci- clinically significant depressive symptoms compared with ficity of this Center for Epidemiological Studies Depression those randomized to HT. During 12 months of continuous treat- Scale cutoff are 87% and 70%, respectively. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition?

Joffe, Hadine; Hickey, Martha
JAMA Psychiatry , Volume 75 (2) – Feb 10, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/should-hormone-therapy-be-used-to-prevent-depressive-symptoms-during-6v8tFRX3VU
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2017.3945
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition? Hadine Joffe, MD, MSc; Martha Hickey, BA(Hons), MBChB, MSc, FRCOG, FRANZCOG, MD In this issue of JAMA Psychiatry, Gordon et al report results of this subgroup (42 women), this observation is consistent with larger prospective studies indicating that the early peri- from a 12-month randomized clinical trial of estrogen plus pro- gestin hormone therapy (HT) vs placebo for the prevention of menopause confers heightened vulnerability to depressive 8,9 depressive symptoms in 172 symptoms, perhaps owing to greater variability in circulat- euthymic perimenopausal ing estradiol concentrations during this reproductive stage. Related article page 149 and early postmenopausal A limitation of this study is that we do not know whether women. Using a random- women who developed elevated Center for Epidemiological ized, parallel-arm placebo-controlled design, they found that Studies Depression Scale scores were experiencing an epi- women assigned to placebo were twice as likely to develop sode of major depression because the sensitivity and speci- clinically significant depressive symptoms compared with ficity of this Center for Epidemiological Studies Depression those randomized to HT. During 12 months of continuous treat- Scale cutoff are 87% and 70%, respectively.

Journal

JAMA Psychiatry – American Medical Association

Published: Feb 10, 2018

References

  • Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial [published online January 10, 2018]
    Gordon, JL; Rubinow, DR; Eisenlohr-Moul, TA; Xia, K; Schmidt, PJ; Girdler, SS
  • The 2017 hormone therapy position statement of The North American Menopause Society
  • Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study
    Santoro, N; Allshouse, A; Neal-Perry, G
  • Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause
    Hale, GE; Burger, HG
  • Longitudinal pattern of depressive symptoms around natural menopause
    Freeman, EW; Sammel, MD; Boorman, DW; Zhang, R
  • Associations of hormones and menopausal status with depressed mood in women with no history of depression
    Freeman, EW; Sammel, MD; Lin, H; Nelson, DB
  • Independent contributions of nocturnal hot flashes and sleep disturbance to depression in estrogen-deprived women
    Joffe, H; Crawford, SL; Freeman, MP
  • Depressive symptoms across the menopause transition: findings from a large population-based cohort study
    Hickey, M; Schoenaker, DA; Joffe, H; Mishra, GD
  • Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women
    Bromberger, JT; Assmann, SF; Avis, NE; Schocken, M; Kravitz, HM; Cordal, A
  • Screening for depression in the general population with the Center for Epidemiologic Studies Depression (CES-D): a systematic review with meta-analysis
    Vilagut, G; Forero, CG; Barbaglia, G; Alonso, J
  • Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial
    Christensen, H; Batterham, PJ; Gosling, JA
  • Telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: a MsFLASH randomized clinical trial
    McCurry, SM; Guthrie, KA; Morin, CM
  • Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials
    Manson, JE; Aragaki, AK; Rossouw, JE
  • Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial
    Rossouw, JE; Anderson, GL; Prentice, RL